Drug GMP Investor Alerts in Brief
This article was originally published in The Gold Sheet
Executive Summary
Pharmaceutical manufacturers alerted investors to manufacturing quality issues that arose in the quarter ending June 30, including: Actavis, Acorda, Perrigo, Impax, Cubist, Aastrom and Amphastar.
You may also be interested in...
Perrigo Growth Trajectory Traverses Manufacturing, Licensing Headwinds
Perrigo omitted from its fiscal 2015 guidance revenues from generic guaifenesin expectorants because raw material sourcing has not met manufacturing specifications and continues to hold up production. The firm’s plans for launching store brand OTC nasal corticosteroids also are in limbo.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.